Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.
Okamura Y, Boku N, Ghaneh P, Greenhalf W, Yasukawa S, Narimatsu H, Fukutomi A, Konishi M, Morinaga S, Toyama H, Maeda A, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Takayama W, Yamaguchi R, Tomikawa M, Yanagisawa A, Neoptolemos JP, Uesaka K. Okamura Y, et al. Among authors: morinaga s. Cancer Rep (Hoboken). 2022 May;5(5):e1507. doi: 10.1002/cnr2.1507. Epub 2021 Jul 29. Cancer Rep (Hoboken). 2022. PMID: 34327872 Free PMC article.
Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y. Morinaga S, et al. Ann Surg Oncol. 2012 Jul;19 Suppl 3:S558-64. doi: 10.1245/s10434-011-2054-z. Epub 2011 Sep 13. Ann Surg Oncol. 2012. PMID: 21913012
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Ohkawa S, Akaike M, Yamamoto N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. Cancer Chemother Pharmacol. 2014 Dec;74(6):1235-40. doi: 10.1007/s00280-014-2601-y. Epub 2014 Oct 9. Cancer Chemother Pharmacol. 2014. PMID: 25297990
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T, Katayama Y, Murakawa M, Atsumi Y, Yamaoku K, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. Cancer Chemother Pharmacol. 2015 Jun;75(6):1115-20. doi: 10.1007/s00280-015-2736-5. Epub 2015 Mar 29. Cancer Chemother Pharmacol. 2015. PMID: 25821166
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: morinaga s. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy.
Aoyama T, Kazama K, Miyagi Y, Murakawa M, Yamaoku K, Atsumi Y, Shiozawa M, Ueno M, Morimoto M, Oshima T, Yukawa N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. Oncol Lett. 2017 Jul;14(1):599-606. doi: 10.3892/ol.2017.6220. Epub 2017 May 19. Oncol Lett. 2017. PMID: 28693211 Free PMC article.
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group. Hagiwara Y, et al. Among authors: morinaga s. Eur J Cancer. 2018 Apr;93:79-88. doi: 10.1016/j.ejca.2018.01.081. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29477795 Clinical Trial.
Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy.
Aoyama T, Atsumi Y, Kazama K, Murakawa M, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yukawa N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. J Cancer Res Ther. 2018 Dec;14(Supplement):S1129-S1134. doi: 10.4103/0973-1482.194927. J Cancer Res Ther. 2018. PMID: 30539858 Free article.
495 results